Laurus Labs: Final Thoughts
The company has announced a price range of Rs 426 - 428 per share for its listing with bidding set to open on 6 December and closing on 8 December...
354 Views
No Trump Cards for This Risk
This Insight is an update from Generic Drug Antitrust Inquiry: A Primer. Several generic drug companies caught up in government investigations into...
353 Views
Generic Drug Antitrust Inquiry: A Primer
Recent news stories reporting looming criminal antitrust charges against certain generic drug companies (and possibly executives) are wighing on...
393 Views
Mylan N.V. (MYL US): Another Contrarian Pharmaceutical Investment
Mylan Nv (MYL US) stock has seen some downward pressure since 2015 after the increased capital expenditure and debt load for acquisitions...
624 Views
Neurocrine Biosciences: An Attractive Takeover Candidate with Potential >50% Upside.
FDA has accepted the New Drug Application (NDA) for Neurocrine Biosciences Inc (NBIX US) Valbenazine for the treatment of Tardive Dyskinesia (with...
576 Views